Trilaciclib-Chemo Combo Extends Lives of Triple-negative Breast Cancer Patients, Preliminary Phase 2 Findings Show
Trilaciclib,
a treatment that protects the bone marrow from the damaging effects of
chemotherapy, significantly extends the lives of women with metastatic triple-negative breast cancer receiving a chemotherapy regimen of gemcitabine and carboplatin, G1 Therapeutics
announced.
Chemotherapy kills tumor cells that divide rapidly. However, a major
side effect is that it also kills rapidly-dividing healthy cells,
including important stem cells in the bone marrow. Those stem cells
produce white blood cells, red blood cells, and platelets.
Therefore, most chemotherapy agents cause bone marrow toxicity as a
secondary effect. That leads patients to reduce their chemotherapy dose,
or stop the treatment, which increases the chances of cancer
progression.
Trilaciclib, developed by G1 Therapeutics, is a myelopreservation agent —
meaning it protects the bone marrow from damage caused by chemotherapy.
Combining chemotherapy and myelopreservation agents increases the
amount of chemotherapy that individuals can tolerate, thus improving
patient outcomes.
The treatment's protective effects were demonstrated in lung cancer
patients, but their need for supportive care and dose reductions is
significantly lower. Now, trilaciclib is being evaluated in metastatic
triple-negative breast cancer patients — a population whose chemotherapy
treatment is often limited by bone marrow toxicity.
An ongoing, randomized, Phase 2 clinical trial
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot delete your posts in this forum You cannot edit your posts in this forum You cannot create polls in this forum You cannot vote in polls in this forum